Research programme: coronavirus inhibitors - TaiGen
Alternative Names: Anti-SARS protease inhibitor - TaiGen; Coronavirus inhibitors research programme - TaiGen; TD 0205221Latest Information Update: 16 Jul 2016
At a glance
- Originator TaiGen Biotechnology
- Class Carbamates; Dipeptides
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Severe acute respiratory syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Severe acute respiratory syndrome in Taiwan
- 30 Oct 2003 Preclinical trials in Severe acute respiratory syndrome in Taiwan (unspecified route)